31 results on '"Mansfield, A.S."'
Search Results
2. Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer
3. Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer
4. EP14.04-01 BRCA-Associated Protein-1 (BAP1) Loss and Real-World Outcomes of Immune Checkpoint Inhibitor Therapy in Pleural Mesothelioma.
5. P2.16-03 RYZ101 + Carboplatin + Etoposide + Atezolizumab in Somatostatin Receptor Expressing Extensive-Stage Small-Cell Lung Cancer.
6. EP11.03-26 Real-World Outcomes with Immunotherapy Compared to Chemoimmunotherapy in Metastatic NSCLC with High PDL1 Expression.
7. MA17.10 miRNA Signatures In Mesothelioma and their Associations with Outcomes with Immune Checkpoint Inhibitors.
8. OA02.04 Phase 1/2 Randomized Trial of Anetumab Ravtansine and Pembrolizumab Compared to Pembrolizumab for Pleural Mesothelioma - NCT03126630.
9. Severe hepatic dysfunction is associated with venous thromboembolic events in phase 1 clinical trials.
10. EP08.02-037 Small Cell Transformation in a Patient with RET Fusion Positive Lung Adenocarcinoma on Pralsetinib.
11. VP5-2021: IMpower133: Gene expression (GE) analysis in long-term survivors (LTS) with ES-SCLC treated with first-line carboplatin and etoposide (CE) ± atezolizumab (atezo).
12. 88P: Use of brain imaging in the management of patients with lymph node negative multifocal lung cancer.
13. 70 Heterogeneity of programmed death-ligand 1 expression in multifocal lung cancer.
14. 115 Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer.
15. 1654P Updated ARROW data: Pralsetinib in patients (pts) with advanced or metastatic RET-altered thyroid cancer (TC).
16. Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial.
17. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.
18. 1346P Comparison of clinical outcomes of patients with METΔex14 NSCLC treated with first-line capmatinib in the GEOMETRY mono-1 study with those of a cohort of real-world patients.
19. LBA5 Amivantamab plus chemotherapy vs chemotherapy as first-line treatment in EGFR Exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): Primary results from PAPILLON, a randomized phase III global study.
20. LBA71 First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (uMPM): 4-year update from CheckMate 743.
21. Meta-analysis on anticoagulation and prevention of thrombosis and mortality among patients with lung cancer.
22. Prospective evaluation of protein C and factor VIII in prediction of cancer-associated thrombosis.
23. Ablative Radiotherapy for Ultracentral Primary Non-Small Cell Lung Cancer: Dosimetric and Anatomic Predictors of Outcomes and Toxicities.
24. Adjuvant Radiation Therapy for Pleural Mesothelioma after Extrapleural Pneumonectomy (EPP) or Pleurectomy and Decortication (P+D).
25. 84MO Tumour-only sequencing led to inflated tumour mutational burden estimation especially in under-represented ethnic groups.
26. Prospective Immunophenotyping of CD8+ T-cells and Associated Clinical Outcomes of Patients with Oligometastatic Prostate Cancer Treated with Metastasis-Directed Stereotactic Body Radiation Therapy.
27. 1285P Capmatinib in patients with METex14-mutated advanced non-small cell lung cancer who received prior immunotherapy: The phase II GEOMETRY mono-1 study.
28. 1913O Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC).
29. 1026MO Phase Ib dose escalation study of novel immunogenic cell death (ICD) inducer PT-112 plus PD-L1 inhibitor avelumab in solid tumours.
30. CD11ahighCD8+ T Cell Phenotype Identifies Tumor Specific Effector Cells Whose Frequency and Function Are Enhanced by RT.
31. Early Venous Thromboembolic Events Are Associated With Worse Prognosis in Patients With Lung Cancer: Supportive Care/Palliation/Nursing.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.